Lindvi Gudmundsdotter

This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Affibody Ab, Abclon Inc.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lindvi Gudmundsdotter. Retrieved from https://idiyas.com/inventor/lindvi-gudmundsdotter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 3.6

ph-index = 1

Company Filing History:

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12221464 - Methods of treatment of IL-17A associated conditions (2025-02-11),

2. 10934335 - IL-17A-binding polypeptides (2021-03-02),

3. 10633423 - IL-6-binding polypeptide complex (2020-04-28),

4. 10323066 - Neonatal Fc receptor binding dimer and methods of use (2019-06-18),

Title: Lindvi Gudmundsdotter: Innovator in Therapeutic Polypeptides

Introduction

Lindvi Gudmundsdotter is a prominent inventor based in Stockholm, Sweden. With a remarkable portfolio of four patents, she has made significant contributions to the field of biotechnology, particularly in the development of engineered polypeptides.

Latest Patents

Among her latest patents, Gudmundsdotter has disclosed methods of treating IL-17A associated conditions. This groundbreaking work includes a class of engineered polypeptides with a binding affinity for interleukin-17A (IL-17A). Her patent provides an IL-17A binding polypeptide comprising the sequence EXDXAXXEIXXLPNL XXXQXXAFIXXLXX, which can be used as a diagnostic, prognostic, and/or therapeutic agent.

Career Highlights

Over her career, Gudmundsdotter has worked with notable companies in the biotechnology sector. Among them are Affibody AB and Abclon Inc., where she has contributed her expertise in polypeptide engineering and therapeutic development.

Collaborations

Lindvi Gudmundsdotter has collaborated with esteemed professionals, including Fredrik Frejd and Joachim Feldwisch. These partnerships have fostered innovation and advanced research in her field, further demonstrating her capability as a leading inventor.

Conclusion

Lindvi Gudmundsdotter continues to push the boundaries of scientific innovation in therapeutic applications. Her valuable patents and collaborative efforts reflect her commitment to advancing biotechnology and addressing critical health conditions. Her work promises to impact the medical field positively and drive future research initiatives.

Profile summary based on public USPTO records.